A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.
(2008) Cancer Investigation — Vol. 26, n° 3, p. 269-277 (2008)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- Dose-dense temozolomide schedules deplete O6-methylguanine methyltransferase and may overcome chemoresistance. This multicenter cohort study enrolled 19 patients (15 anaplastic astrocytoma, 4 anaplastic oligoastrocytoma) who received temozolomide (100 mg/m2/day for 21 consecutive days every 28-day cycle) at first recurrence, either until disease progression or 12 cycles. Six-month progression-free survival was 56%, comparing favorably with historic controls treated with the standard 5-day temozolomide schedule. Median survival was 12.9 months (95% CI: 3.7, 22 months). Among 15 evaluable patients, 2 had a complete or partial response, and 10 had stable disease. Grade 3 and 4 lymphopenia occurred in 53% and 47% of patients, respectively.
- Affiliations
Citations
Neyns, B., Chaskis, C., Joosens, E., Menten, J., D’Hondt, L., Branle, F., Sadones, J., & Michotte, A. (2008). A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Investigation, 26(3), 269-277. https://doi.org/10.1080/07357900701708393 (Original work published 2008)